InterCure (INCR) Competitors $1.54 -0.01 (-0.32%) Closing price 03:57 PM EasternExtended Trading$1.56 +0.03 (+1.63%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INCR vs. ALLO, TVRD, ZYBT, CRDF, MREO, KOD, MNPR, TSVT, AARD, and PRQRShould you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), Zhengye Biotechnology (ZYBT), Cardiff Oncology (CRDF), Mereo BioPharma Group (MREO), Kodiak Sciences (KOD), Monopar Therapeutics (MNPR), 2seventy bio (TSVT), Aardvark Therapeutics (AARD), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. InterCure vs. Its Competitors Allogene Therapeutics Tvardi Therapeutics Zhengye Biotechnology Cardiff Oncology Mereo BioPharma Group Kodiak Sciences Monopar Therapeutics 2seventy bio Aardvark Therapeutics ProQR Therapeutics InterCure (NASDAQ:INCR) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Which has higher valuation and earnings, INCR or ALLO? InterCure has higher revenue and earnings than Allogene Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterCure$64.55MN/A-$18.32MN/AN/AAllogene TherapeuticsN/AN/A-$257.59M-$1.23-1.22 Is INCR or ALLO more profitable? InterCure's return on equity of 0.00% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InterCureN/A N/A N/A Allogene Therapeutics N/A -52.98%-41.28% Do analysts rate INCR or ALLO? Allogene Therapeutics has a consensus target price of $8.44, suggesting a potential upside of 462.96%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has more risk and volatility, INCR or ALLO? InterCure has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Do insiders and institutionals have more ownership in INCR or ALLO? 8.3% of InterCure shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor INCR or ALLO? In the previous week, Allogene Therapeutics had 1 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Allogene Therapeutics and 1 mentions for InterCure. InterCure's average media sentiment score of 1.89 beat Allogene Therapeutics' score of 0.96 indicating that InterCure is being referred to more favorably in the media. Company Overall Sentiment InterCure Very Positive Allogene Therapeutics Positive SummaryInterCure and Allogene Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get InterCure News Delivered to You Automatically Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCR vs. The Competition Export to ExcelMetricInterCureMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.18M$10.55B$5.70B$9.51BDividend YieldN/A2.00%4.69%4.01%P/E RatioN/A17.0728.0720.05Price / SalesN/A29.18448.5799.42Price / CashN/A23.0336.2258.56Price / Book0.653.698.665.87Net Income-$18.32M$234.77M$3.25B$258.55M7 Day Performance0.99%6.32%4.20%2.23%1 Month Performance3.72%8.39%10.82%12.76%1 Year Performance-36.31%-13.51%34.70%19.36% InterCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCRInterCure0.661 of 5 stars$1.54-0.3%N/A-34.5%$70.18M$64.55M0.00350Positive NewsALLOAllogene Therapeutics3.2575 of 5 stars$1.29+0.8%$8.44+554.6%-48.1%$282.16M$20K-1.05310TVRDTvardi TherapeuticsN/A$29.83+9.1%$64.25+115.4%N/A$279.21M$7.14M0.0080High Trading VolumeZYBTZhengye BiotechnologyN/A$5.87-0.3%N/AN/A$276.86M$186.36M0.00278Positive NewsGap UpCRDFCardiff Oncology1.1483 of 5 stars$4.13+1.5%$11.70+183.3%+82.4%$274.77M$680K-4.4920MREOMereo BioPharma Group1.7907 of 5 stars$1.72+6.8%$7.20+318.6%-55.9%$273.48M$10M-24.5740High Trading VolumeKODKodiak Sciences2.5305 of 5 stars$5.17+14.1%$9.00+74.1%+173.2%$272.77MN/A-1.4290MNPRMonopar Therapeutics2.2868 of 5 stars$43.73+18.6%$60.00+37.2%+1,363.1%$267.63MN/A-12.5710Positive NewsTSVT2seventy bio0.3457 of 5 stars$5.00flat$5.00N/A$266.15M$48.37M-2.69440AARDAardvark TherapeuticsN/A$12.11-0.5%$33.00+172.5%N/A$262.74MN/A0.0018PRQRProQR Therapeutics2.8831 of 5 stars$2.48+6.9%$8.00+222.6%+20.2%$260.92M$20.46M-7.09180 Related Companies and Tools Related Companies ALLO Competitors TVRD Competitors ZYBT Competitors CRDF Competitors MREO Competitors KOD Competitors MNPR Competitors TSVT Competitors AARD Competitors PRQR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCR) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
